- Home
- CYCN vs PMCB Comparison
CYCN vs PMCB Comparison
Compare CYCN & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- PMCB
- Stock Information
- Founded
- CYCN 2018
- PMCB 1996
- Country
- CYCN United States
- PMCB United States
- Employees
- CYCN N/A
- PMCB 2
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CYCN Health Care
- PMCB Health Care
- Exchange
- CYCN Nasdaq
- PMCB Nasdaq
- Market Cap
- CYCN 7.6M
- PMCB 6.6M
- IPO Year
- CYCN N/A
- PMCB N/A
- Fundamental
- Price
- CYCN $2.25
- PMCB $0.98
- Analyst Decision
- CYCN
- PMCB
- Analyst Count
- CYCN 0
- PMCB 0
- Target Price
- CYCN N/A
- PMCB N/A
- AVG Volume (30 Days)
- CYCN 1.1M
- PMCB 109.4K
- Earning Date
- CYCN 11-13-2025
- PMCB 09-15-2025
- Dividend Yield
- CYCN N/A
- PMCB N/A
- EPS Growth
- CYCN N/A
- PMCB N/A
- EPS
- CYCN N/A
- PMCB 0.01
- Revenue
- CYCN $2,174,000.00
- PMCB N/A
- Revenue This Year
- CYCN N/A
- PMCB N/A
- Revenue Next Year
- CYCN N/A
- PMCB N/A
- P/E Ratio
- CYCN N/A
- PMCB $154.00
- Revenue Growth
- CYCN N/A
- PMCB N/A
- 52 Week Low
- CYCN $1.27
- PMCB $0.80
- 52 Week High
- CYCN $9.47
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- CYCN 42.18
- PMCB 47.21
- Support Level
- CYCN $2.23
- PMCB $0.94
- Resistance Level
- CYCN $2.46
- PMCB $1.05
- Average True Range (ATR)
- CYCN 0.18
- PMCB 0.05
- MACD
- CYCN -0.03
- PMCB -0.01
- Stochastic Oscillator
- CYCN 19.05
- PMCB 33.33
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.